Last reviewed · How we verify
Aplidin®
Aplidin is a chemotherapeutic agent that works by inhibiting the enzyme histone deacetylase (HDAC).
Aplidin is a chemotherapeutic agent that works by inhibiting the enzyme histone deacetylase (HDAC). Used for Relapsed or refractory multiple myeloma.
At a glance
| Generic name | Aplidin® |
|---|---|
| Also known as | plitidepsin |
| Sponsor | PharmaMar |
| Drug class | Histone deacetylase inhibitor |
| Target | Histone deacetylase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This inhibition leads to an increase in histone acetylation, which in turn causes a decrease in the expression of genes involved in cell proliferation and survival. As a result, Aplidin exerts its anti-tumor effects by inducing apoptosis and cell cycle arrest in cancer cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Fatigue
- Nausea
Key clinical trials
- Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide (PHASE2)
- A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer (PHASE2)
- Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma (PHASE1)
- Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis (PHASE2)
- Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia (PHASE1, PHASE2)
- Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma (PHASE2)
- A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aplidin® CI brief — competitive landscape report
- Aplidin® updates RSS · CI watch RSS
- PharmaMar portfolio CI